This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Cas-Br-M ecotropic retroviral transforming sequence b (CBLB)	Studies in murine cells and in mice suggest that inhibiting CBLB could boost the activity of NK T cell agonists to treat cancer. Wild-type mice developed tolerance to NK T cell agonists, whereas Cblb-deficient mice did not. In a mouse model of metastatic melanoma, <i>Cblb</i> knockout led to fewer lung metastases than those found in wild-type mice during treatment with the agonists. Next steps could include identifying inhibitors of CBLB for use as adjuvants to NK T cell agonist therapy. SciBX 2(40); doi:10.1038/scibx.2009.1498 Published online Oct. 15, 2009	Patent and licensing status unavailable	Kojo, S. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Oct. 5, 2009; doi:10.1073/pnas.0904078106 Contact: Yun-Cai Liu, La Jolla Institute for Allergy and Immunology, La Jolla, Calif. e-mail: yuncail@liai.org